

IN THE CLAIMS:

Please amend claims 36 and 41, and cancel claims 26-30 and 32 as set forth in the complete claim listing below. This listing of claims will replace all prior versions and listings of claims in the application:

1-35. (Canceled).

36.(Currently Amended) A method of treating a patient having a tumor comprising malignant cancer cells having an operative retinoblastoma (RB) protein, by dephosphorylizing the RB protein in said cancer cells and continuously maintaining a dephosphorylated state of the RB in said cancer cells to induce apoptosis thereof, comprising the steps of:

~~systemically~~ administering to said patient in need thereof a pharmaceutically effective dosage of a drug to cause an increase in intracellular redox potential (E) and decrease in the $[GSH]^2/[GSSG]$ (wherein [GSH] is the concentration of glutathione and [GSSG] is the concentration of glutathione disulfide) ratio in the malignant cancer cells of said tumor, said drug comprising a combination of two E-increasing agents disulfram and curcumin and two enzyme deactivating agents bis-chloronitrosourea (BCNU) and buthionine sulfoximine (BSO);

 said pharmaceutically effective dosage of said drug further comprising a ~~a~~ plurality of separate dosage units of said drug administered in a cumulative amount of from 0.01-8 grams per day of said E-increasing agent as needed to continuously maintain said decreased $[GSH]^2/[GSSG]$

ratio in the malignant cells and consequently continuously maintain said dephosphorylated state of the RB in said cancer cells within a range of from 15 to 75 hours in order to span at least one cell cycle, and a minimum effective amount of said enzyme deactivating agent to cause regression of said tumor.

37-40. (Canceled).

41.(Currently Amended) A method of treating a patient having a tumor comprising malignant cancer cells having an operative retinoblastoma (RB) protein, by dephosphorylizing the RB protein in said cancer cells and continuously maintaining a dephosphorylated state of the RB in said cancer cells to induce apoptosis thereof, comprising the steps of:

~~systemically~~ administering to said patient in need thereof a pharmaceutically effective dosage of a drug consisting of disulfiram, curcumin, bis-chloronitrosourea (BCNU) and buthionine sulfoximine (BSO) in a pharmaceutically acceptable carrier, ~~periodically within a range of from 1-8 grams per day~~ as needed to cause an increase in intracellular redox potential (E) and decrease in the $[GSH]^2/[GSSG]$ (wherein [GSH] is the concentration of glutathione and [GSSG] is the concentration of glutathione disulfide) ratio in the malignant cancer cells of said tumor and to continuously maintain said decreased $[GSH]^2/[GSSG]$ ratio within a range of from 15 to 75 hours.